Related Experiment Videos

Once-weekly erythropoietic therapy: is there a difference between the available preparations?

Iain C Macdougall

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association

|November 28, 2002

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Prognostic Relevance of Erythropoiesis-Stimulating Agent Dose Requirements in PIVOTAL and its Implications for the Potential Mechanisms of Intravenous Iron Benefit in Maintenance Hemodialysis Patients.

American journal of nephrology·2026

Cardiovascular Trials in Hemodialysis: Closing the Evidence Gap.

Journal of the American College of Cardiology·2026

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes.

European journal of heart failure·2025

Effects of Ferric Derisomaltose in Heart Failure with Iron Deficiency according to Renal Function in the IRONMAN Randomised Controlled Trial.

American journal of nephrology·2025

Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial.

European journal of heart failure·2025

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials.

European journal of heart failure·2025

See all related articles